Results 71 to 80 of about 75,705 (253)
Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data
Juan Pedro López-Siguero,1 Roland Pfäffle,2 Philippe Chanson,3 Mieczyslaw Szalecki,4,5 Nadja Höbel,6 Markus Zabransky6 1Servicio de Endocrinología Pediátrica, Hospital Materno-Infantil, Hospital Regional Universitario de M&
López-Siguero JP +5 more
doaj
A novel resistance mechanism is mediated through phagocytosis of cancer cells by AR+ TAMs. This process, dependent on ANXA2, enables macrophages to acquire AR protein from engulfed tumor cells. The internalized AR translocates into the macrophage nucleus, where it binds directly to the IL‐6 promoter, augmenting IL‐6 transcription and secretion ...
Yong Luo +13 more
wiley +1 more source
Background The purpose of this study is to evaluate the retinal and choroidal microvascular state in children with congenital isolated growth hormone deficiency (IGHD) and determine the effect of recombinant human growth hormone treatment on these ...
Ismail Omar +2 more
doaj +1 more source
Recombinant hormones from fragments of human growth hormone and human placental lactogen.
Peptide fragments generated by limited plasmin digestion and reduction of human growth hormone (hGH) and human placental lactogen (hPL) were recombined to produce biologically active molecules consisting of the NH2-terminal two-thirds of one hormone molecule linked to the COOH-terminal one-third of the other. Plasmin-cleaved hPL and hGH each consist of
J, Russell +3 more
openaire +2 more sources
Mechanosensitive Piezo1/Osteocalcin/Irisin Axis Protects Against Disuse‐Induced Muscle Atrophy
Mechanical unloading suppresses bone Piezo1 expression, which reduces circulating undercarboxylated osteocalcin (unOCN). unOCN reduction subsequently exacerbates IMM‐induced Fndc5/Irisin decrease and drives severe muscle atrophy. Bone Piezo1 activation or exogenous osteocalcin/Irisin ameliorate muscle atrophy, while muscle‐specific Gprc6a or Fndc5 ...
Zhaolu Wang +5 more
wiley +1 more source
Ten years of biosimilar recombinant human growth hormone in Europe
Paul Saenger Division of Pediatric Endocrinology, Department of Pediatrics, Winthrop University Hospital, Mineola, NY, USA Abstract: Recombinant human growth hormone (rhGH) has been in clinical use for more than 30 years.
Saenger P
doaj
The long-acting growth hormone (LAGH) is a promising alternative biopharmaceutical to treat growth hormone (GH) deficiency in children, and it was developed using a variety of technologies by several pharmaceutical companies. Most LAGH preparations, such
Wenrong Yao +8 more
doaj +1 more source
To determine the auxological response to recombinant human growth hormone (rhGH) therapy in children with growth hormone deficiency (GHD) presenting at the National Institute of Child Health, Karachi, Pakistan. Observational study. Place and Duration of the Study: Department of Paediatric Endocrinology, National Institute of Child Health, Karachi ...
Maira, Riaz +5 more
openaire +2 more sources
CAF‐derived S1P activates the S1PR3‐JNK‐Jun signaling pathway, thereby transcriptionally upregulating MALL expression in cancer cells. MALL increases the cell‐surface abundance of SDC4 by promoting its recycling and restricting its lysosomal degradation, which in turn enhances RhoA‐p‐MLC2‐dependent amoeboid invasion and SDC4‐PTN axis‐mediated cancer ...
Wang Peng +16 more
wiley +1 more source
Lactational lactoferrin deficiency exerts lasting effects on epididymal adipose tissue development from lactation into adulthood: it impairs adipocyte hyperplasia and induces pathological hypertrophy, resulting in lower body weight yet exacerbated metabolic dysfunction under a high‐fat diet in adulthood.
Qin An +11 more
wiley +1 more source

